
usd apr pm et
summari compani develop novel antibodi therapeut target varieti rare sever
diseas state includ autoimmun disord inflamm cancer
price-to-earnings oper ep
depend sale drug
make compani vulner weak sale
obsolesc major product howev
promis pipelin low level debt posit
cash flow recent year bode well
compani abil remain go concern
jul ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
apr stock trade
look sale rise
driven growth combin
sale soliri ultomiri
follow combin sale growth
expect sale strensiq
grow slowdown
growth
diseas therapi pipelin
wilson diseas area
new treatment year expect
leverag expertis manag rare diseas
treatment success launch
known
phase switch data
 ultomiri show patient
effect safe switch treatment
soliri everi two week treatment
everi eight week safeti profil
consist soliri total
data favor soliri launch
sale ultomiri decemb aim
convert pnh patient soliri
ultomiri end
think trade
ep estim
under-valued still urg caution
concentr primari drug soliri
product revenu think
sever catalyst signific
upsid potenti given expertis
manag develop market
rare diseas treatment high
expect expand indic
soliri convers elig soliri patient
ultomiri late-stag pipelin product
convers ultomiri
import futur drug
like insul soliri certain
indic biosimilar competit
expect threat three four year
risk recommend target price
includ weak sale growth soliri
slower-than-expect convers soliri
patient ultomiri pipelin failur
competit threat unfavor chang
target price base
peer ep
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview develop novel antibodi therapeut target
varieti sever disord includ autoimmun cardiovascular diseas inflamm cancer
global leader complement inhibit first market product soliri eculizumab
first therapi approv treatment patient paroxysm nocturn hemoglobinuria pnh
soliri design inhibit specif aspect complement compon immun system
therebi treat inflamm associ chronic hematolog neurolog disord transplant
reject autoimmun disord
soliri compris alxn product revenu soliri human monoclon antibodi
complement inhibitor block cleavag compon complement cascad
prevent final stage complement activ soliri approv treatment pnh atyp
hemolyt urem syndrom ahu gener myasthenia gravi gmg europ japan
sever countri
latest commerci market drug ultomiri formerli approv decemb
fda treatment patient pnh announc top-lin phase
switch data ultomiri show patient paroxysm nocturn
hemoglobinuria pnh effect safe switch treatment soliri everi week treatment
ultomiri everi week ultomiri safeti profil consist soliri total data
favor ultomiri soliri aim convert pnh patient soliri ultomiri end
also work phase clinic trial ultomiri ahu gmg diseas
current address alxn drug soliri
also market strensiq hypophosphatasia kanuma lyosom acid lipas defici
lal-d decemb three phase clinic program one phase ii program
impact major develop complet acquisit syntimmun inc
clinical-stag biotechnolog compani develop antibodi therapi target neonat fc receptor
fcrn million potenti addit milestone-depend payment
million lead candid acquisit monoclon antibodi
inhibit interact fcrn immunoglobulin igg igg immun complex
studi phase trial treatment igg-medi autoimmun diseas
may acquir wilson therapeut ab total consider million result
acquisit ad pipelin candid highli innov drug candid
current earli stage phase clinic trial treatment patient wilson
diseas pipelin
prior last major acquisit june acquir synageva biopharma
geva nr billion consist cash share
geva share geva kanuma treatment lysosom acid lipas defici orphan drug statu
us eu
financi trend alxn sale increas year-over-year billion billion
reflect five-year compound annual growth rate compound-annual-growth-rate compani ep expand
year-over-year reflect five-year compound-annual-growth-rate given compani low debt level
decemb posit free cash flow past five fiscal year think
well-posit continu fund research develop effort even extern
financ becom significantli limit decemb leverag ratio net debt
trailing-twelve-month ebitda annual million
independ chairman
board
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
neutral sinc april technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit outlook biotechnolog
histor defens sub-industri
expect see commerci
develop mani new innov therapi
declin preval patent
expir biotechnolog
compani trade discount
market think remedi
robust pipelin new drug brought
market fda approv novel drug increas
shatter
previou record sinc novel
approv set think mani
drug either newly-approv
late-stag clinic trial consider
commerci prospect repres major
advanc therapi diseas
sclerosi cancer
start favor
announc mega merger agreement
celgen celg bristol-my
squibb industri debt level
still low risen last four
five year suggest may
banner year biotech merger
acquisit although
sever matur biopharmaceut firm
made mark blockbust drug
look off-set lost revenu
expir patent fail ventur
exampl see
like acquir
expect interest
off-set declin hcv therapi sale
expect engag activ make
failur late-stag alzheim
low debt level attract valuat
rel industri make
think growth biotechnolog
stock limit recent high
drug price come
heighten scrutini polit
apparatu last year despit
talk lower drug price
seen particularli sever measur taken
legisl regulatori bodi
lower drug price democrat took
hous repres
novemb mid-term elect appear
motiv address drug price
still think suffici impetu
effect signific chang near
futur anoth sourc price pressur
drug manufactur pharmaci benefit
manag pbm health insur
exert influenc drug
prescript price pressur
like increas major pbm merg
major insur cvs-aet ci-esrx
biolog price competit innov
act bpcia grant
exclus period brand biolog maker
sinc brand biolog manufactur
aggress use patent law
commerci leverag delay
commerci biosimilar
maintain market domin longer
result expect biosimilar continu
advanc slowli next sever year
year-to-d april
biotechnolog index risen mere
compar rise valu
 composit index
declin
base index
five-year market price perform apr
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
revenu new indic rais ep
ep think soliri launch treatment
myasthenia gravi approv octob perform better expect
reflect expertis manag develop market
rare diseas treatment see upsid pipelin particularli
expect launch upon approv
regulatori bodi also see posit potenti june acquisit
wilson ad anoth late-stag rare diseas therapi
much upsid potenti caution
compani risk still highli concentr primari drug soliri
gener revenu /kevin huang cfa
rais target price
slightli peer forward ep estim
see grow faster peer posit view
rare diseas pipelin ep vs ahead
estim rais ep estim ep
estim sale rose volum rose driven
robust launch soliri treat gener myasthenia gravi gmg overal
soliri sale rose volum growth strensiq sale rose
kanuma sale rose encourag pipelin progress
file approv treat paroxysm nocturn hemoglobinuria
pnh europ expect file japan phase
trial treat atyp hemolyt urem syndrom ahu
on-going expect data earli /jeffrey loo cfa
analyst research note compani news
pm et cfra reiter buy opinion share alexion
keep target base
multipl ep estim ep
vs significantli exceed consensu estim due
out-performance soliri sale rais ep
sale increas million driven sale soliri
gener myasthenia gravi gmg convers patient ultomiri
core busi growth soliri sale grew million volum
increas ultomiri achiev million sale first full
quarter commerci avail begin week
paroxysm nocturn hemoglobinuria pnh patient convert
treatment soliri ultomiri forecast remain track
convert pnh patient end next catalyst
fda decis soliri neuromyel optica spectrum disord nmosd
action date june /kevin huang cfa
pm et cfra maintain buy opinion share alexion
pharmaceut inc lift target
base in-lin peer multipl ep
estim rais today ep vs
higher estim due stronger-than-expect sale soliri
initi ep sale increas million
soliri sale grew million volum increas ultomiri
approv fda decemb complet
first month sale us januari alreadi convert
soliri paroxysm nocturn hemoglobinuria pnh patient ultomiri
aim convert pnh patient end aggress goal
also intend rapidli expand patient base given goal
price ultomiri favor patient also began proactiv
offer discount strensiq expect price
headwind revenu /kevin huang cfa
inc lift target
above-p ep estim
ep vs higher estim rais
ep lower ep sale
increas million soliri sale grew million
volum increas end septemb gener myasthenia
gravi gmg patient soliri therapi increas
number patient end june launch soliri gmg
turn success soliri launch expect
launch drive continu revenu growth think guidanc
increas quarter larg success gmg launch
also announc collabor discov
develop rnai therapi complement-medi diseas ad four rnai
candid pre-clin develop /kevin huang cfa
et cfra reiter buy opinion share alexion
trade pre-market today
posit top-line result phase prevent studi soliri patient
auto antibody-posit neuromyel optica
spectrum disord nmosd nmosd rare devast central nervou
system disord character relaps result increment
disabl symptom prevent studi met primari endpoint
demonstr treatment soliri reduc risk nmosd relaps
compar placebo current approv therapi
diseas expect detail result phase studi present
buy hold lift target
above-p ep estim
encourag success expans key drug soliri
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
